Next generation sequencing market seen hitting $33.3 billion by 2032

Persistence Market Research projects the global next generation sequencing market will grow from $8.42 billion in 2025 to $33.3 billion by 2032, driven by precision medicine, genomic diagnostics, and broader clinical adoption. North America leads now, while Asia Pacific is expected to be one of the fastest-growing regions.

Why it matters: - Next generation sequencing is becoming a core tool in clinical diagnostics, precision medicine, drug discovery, and life sciences research. - The market’s projected growth signals deeper use of genomic testing across cancer care, rare disease diagnosis, and infectious disease monitoring. - Wider adoption could improve treatment targeting, speed up research workflows, and expand access to genomic analysis.

What happened: - Persistence Market Research projects the global next generation sequencing market will rise from US$ 8.42 billion in 2025 to US$ 33.3 billion by 2032. - The forecast implies a 21.7% compound annual growth rate from 2025 to 2032. - The report points to rising demand for genomic-based diagnostics, more research funding, and broader integration of sequencing into clinical practice. - North America leads the market, while Asia Pacific is emerging as one of the fastest-growing regions. - Get the sample report for more information.

The details: - Sequencing platforms remain the leading product category because of ongoing innovation and higher throughput. - Consumables also drive recurring revenue because each workflow needs reagents, kits, and other lab materials. - Healthcare and research institutions are major end users of next generation sequencing. - Oncology is one of the largest application areas because of demand for personalized cancer treatment. - Other major uses include genetic disease screening, reproductive health, infectious disease monitoring, and agricultural genomics. - Pharmaceutical companies use sequencing in drug discovery and biomarker identification. - Academic institutes and research organizations are expanding genomic research programs. - The market also spans sequencing instruments, software solutions, technology platforms, workflows, hospitals, diagnostic laboratories, biotechnology firms, and pharmaceutical companies. - North America’s lead rests on advanced healthcare infrastructure, strong biotechnology investment, and early precision medicine adoption. - Asia Pacific growth is tied to rising healthcare investment, expanding genomic research, and greater awareness of precision diagnostics. - Europe continues to post growth through clinical research and genomic healthcare initiatives.

Between the lines: - Precision medicine is moving from a niche use case toward a broader clinical standard, and sequencing is riding that shift. - High upfront costs remain a barrier, especially for smaller healthcare facilities and research organizations. - Data management is another constraint because sequencing produces large genomic datasets that require secure storage, advanced analysis, and compliance controls. - The market opportunity is expanding beyond research into population genomics, reproductive health, infectious disease surveillance, and precision oncology. - Artificial intelligence could improve genomic interpretation and clinical decision-making, but the report frames that as an expected development rather than a current standard.

What’s next: - Continued gains in sequencing speed, accuracy, automation, and scalability should support broader clinical and commercial use. - Government support, biotechnology investment, and academic-industry collaboration are likely to keep market growth elevated. - Emerging economies may become a bigger growth engine as healthcare infrastructure and biotech research spending increase. - Key players include Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Agilent Technologies, QIAGEN, PerkinElmer, and Bio-Rad Laboratories. - Request customization or buy the full report for deeper market detail.

The bottom line: - Next generation sequencing is shifting from a specialized research tool to a wider clinical platform, and the market is expected to more than quadruple by 2032.